Scarica l'app Stockscreener
4.82
1.26%
0.06
Dopo l'orario di chiusura:
4.82
Precedente Chiudi:
$4.76
Aprire:
$4.87
Volume 24 ore:
8,702
Relative Volume:
0.60
Capitalizzazione di mercato:
$6.26M
Reddito:
$35.75M
Utile/perdita netta:
$11.57M
Rapporto P/E:
-1.2661
EPS:
-3.8069
Flusso di cassa netto:
$-26.25M
1 W Prestazione:
-7.79%
1M Prestazione:
-25.16%
6M Prestazione:
-46.56%
1 anno Prestazione:
-64.12%
Intervallo 1D:
$4.715
$4.87
Intervallo di 1 settimana:
$4.715
$5.4286
Portata 52W:
$4.715
$20.28
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Confronta RDHL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
4.82 | 6.26M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
165.31 | 74.02B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.90B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.23B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.57 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-08-31 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-11 | Iniziato | BTIG Research | Buy |
| 2019-07-12 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | Iniziato | Nomura | Buy |
| 2017-10-06 | Iniziato | Seaport Global Securities | Buy |
| 2017-10-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-24 | Reiterato | FBR & Co. | Outperform |
| 2016-07-27 | Reiterato | FBR Capital | Outperform |
| 2015-09-29 | Iniziato | Nomura | Buy |
| 2015-07-29 | Reiterato | ROTH Capital | Buy |
| 2015-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-15 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Redhill Biopharma Ltd Adr Borsa (RDHL) Ultime notizie
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
GAMMA Investing LLC Buys 595 Shares of ArcelorMittal S.A. (NYSE:MT) - Defense World
RedHill wins $8 million judgment in New York court - Investing.com India
RedHill Biopharma: FDA Accepts TALICIA’s NDA - Investing.com
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - StockTitan
Can Redhill Biopharma Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
RDHL stock’s current quarter earnings estimates: What analysts predict? - US Post News
Talicia® Launched in the United Arab Emirates - Yahoo Finance
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
Opaganib shows promise in obesity, diabetes treatment - Investing.com
RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib - Investing.com
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo Finance
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
RedHill secures new US patent for H. pylori treatment Talicia - Investing.com
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - PR Newswire
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet - Yahoo Finance
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension - BioSpace
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert
Cathie Wood Predictions 2022 - New Trader U
RedHill presents new Talicia® data analyses at DDW 2022 - EurekAlert
RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha
RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 - BioSpace
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib - Yahoo Finance
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement - Yahoo Finance
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
Is Senseonics Holdings, Inc. (SENS) Going to Burn These Hedge Funds? - Yahoo Finance
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam® - NAI 500
RedHill Biopharma files for further Nasdaq offering - גלובס
RedHill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Redhill Biopharma Ltd Adr Azioni (RDHL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.92%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):